Endocrine Abstracts (2013) 32 P802 | DOI: 10.1530/endoabs.32.P802

GnRH analog treatment in children with congenital adrenal hyperplasia complicated by central precocious puberty

Ayla Guven, Ayse Nurcan Cebeci & Suna Hancili


Pediatric Endocrinology Clinics, Göztepe Education and Research Hospital, Istanbul, Turkey.


Introduction: In children with congenital adrenal hyperplasia (CAH), central precocious puberty (CPP) may occur and this situation may compromise final height. We aimed to evaluate the effect of GnRH analog therapy (GnRHa-T) on growth in children with CAH.

Design: Ten children with CAH were included in ongoing follow-up study. Nine children underwent GnRH stimulation test. GnRHa-T was used as 3.75 mg/q 4 weeks and the dose had to be increased to 7.5 mg/q 4 weeks in two children. Bone ages (BA), growth velocities (GV) and BMIs of patients during treatment were evaluated.

Results: On admission mean chronologic age (CA) and BA were 6.18±2.1 years and 10.5±2 years respectively. Five children have 46,XX karyotype, but one of them was reared as a male. Mean follow-up 4±1.8 years. A significant difference was found between mean BA/CA on admission and at last visit (P=0.002; t: 4933), and between mean BA/CA the beginning of GnRHa-T and at last visit (P=0.002; t: 4453). Mean CA was significantly increased in girls than boys at the beginning of GnRHa-T (8.37±0.9 vs 5.2±1.5 years; P=0.032).

GV was 5.96±2.2, 6.98±2.9 and 4.77±2.8 cm at the end of first (GV1), second (GV2) and third years of the therapy respectively. BMI was inversely correlated with GV1 (r: −0.818; P=0.007) and GV2 (r: −0.731; P=0.039). Mean CA at the beginning of GnRHa-T was negatively correlated with GV1 (r: −0.714; P=0.047) and GV2 (r: −0.927; P=0.003).

On admissionAt the beginning of GnRHa therapyAt last visit on therapy
Mean chronologic age (CA; years)6.18±2.16.78±1.810.1±2
Mean bone age (BA; years)10.5±211.2±1.712.3±2.1
Mean BA/CA1.93±0.61.7±0.41.22±0.2
Mean predicted height (cm)157.6±21161.3±11
Mean BMI–SDS0.62±0.670.77±0.9

Conclusion: GnRHa-T should be considered for augmentation of linear growth in children with CAH complicated with CPP, particularly in children with not too advanced BA for CA.

Article tools

My recent searches

No recent searches.